Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase
- PMID: 34590480
- DOI: 10.1021/acs.jcim.1c00897
Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase
Abstract
Targeted covalent inhibitors (TCIs) bind to their targets in both covalent and noncovalent modes, providing exceptionally high affinity and selectivity. These inhibitors have been effectively employed as inhibitors of protein kinases, with Taunton and coworkers (Nat. Chem. Biol. 2015, 11, 525-531) reporting a notable example of a TCI with a cyanoacrylamide warhead that forms a covalent thioether linkage to an active-site cysteine (Cys481) of Bruton's tyrosine kinase (BTK). The specific mechanism of the binding and the relative importance of the covalent and noncovalent interactions is difficult to determine experimentally, and established simulation methods for calculating the absolute binding affinity of an inhibitor cannot describe the covalent bond-forming steps. Here, an integrated approach using alchemical free-energy perturbation and QM/MM molecular dynamics methods was employed to model the complete Gibbs energy profile for the covalent inhibition of BTK by a cyanoacrylamide TCI. These calculations provide a rigorous and complete absolute Gibbs energy profile of the covalent modification binding process. Following a classic thiol-Michael addition mechanism, the target cysteine is deprotonated to form a nucleophilic thiolate, which then undergoes a facile conjugate addition to the electrophilic functional group to form a bond with the noncovalently bound ligand. This model predicts that the formation of the covalent linkage is highly exergonic relative to the noncovalent binding alone. Nevertheless, noncovalent interactions between the ligand and individual amino acid residues in the binding pocket of the enzyme are also essential for ligand binding, particularly van der Waals dispersion forces, which have a larger contribution to the binding energy than the covalent component in absolute terms. This model also shows that the mechanism of covalent modification of a protein occurs through a complex series of steps and that entropy, conformational flexibility, noncovalent interactions, and the formation of covalent linkage are all significant factors in the ultimate binding affinity of a covalent drug to its target.
Similar articles
-
Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.J Chem Inf Model. 2024 Apr 22;64(8):3488-3502. doi: 10.1021/acs.jcim.4c00023. Epub 2024 Mar 28. J Chem Inf Model. 2024. PMID: 38546820 Free PMC article.
-
Investigating the Impact of Covalent and Non-covalent Binding Modes of Inhibitors on Bruton's Tyrosine Kinase in the Treatment of B Cell Malignancies - Computational Insights.Curr Pharm Biotechnol. 2023;24(6):814-824. doi: 10.2174/1389201023666220617151552. Curr Pharm Biotechnol. 2023. PMID: 35718983
-
Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.Bioorg Med Chem Lett. 2016 Jul 1;26(13):3052-3059. doi: 10.1016/j.bmcl.2016.05.014. Epub 2016 May 7. Bioorg Med Chem Lett. 2016. PMID: 27210433
-
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).Pharmacol Res. 2021 Mar;165:105422. doi: 10.1016/j.phrs.2021.105422. Epub 2021 Jan 9. Pharmacol Res. 2021. PMID: 33434619 Review.
-
Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.Pharmaceuticals (Basel). 2023 Mar 7;16(3):400. doi: 10.3390/ph16030400. Pharmaceuticals (Basel). 2023. PMID: 36986499 Free PMC article. Review.
Cited by
-
QM/MM simulations of EFGR with afatinib reveal the role of the β-dimethylaminomethyl substitution.bioRxiv [Preprint]. 2024 May 8:2024.02.18.580887. doi: 10.1101/2024.02.18.580887. bioRxiv. 2024. PMID: 38766221 Free PMC article. Preprint.
-
Reactivities of acrylamide warheads toward cysteine targets: a QM/ML approach to covalent inhibitor design.J Comput Aided Mol Des. 2024 May 1;38(1):21. doi: 10.1007/s10822-024-00560-6. J Comput Aided Mol Des. 2024. PMID: 38693331
-
Size-Dependent Target Engagement of Covalent Probes.J Med Chem. 2025 Mar 27;68(6):6616-6632. doi: 10.1021/acs.jmedchem.5c00017. Epub 2025 Mar 18. J Med Chem. 2025. PMID: 40099438 Free PMC article.
-
Kinetic Modeling of Covalent Inhibition: Effects of Rapidly Fluctuating Intermediate States.bioRxiv [Preprint]. 2025 May 29:2025.05.28.656658. doi: 10.1101/2025.05.28.656658. bioRxiv. 2025. PMID: 40502015 Free PMC article. Preprint.
-
Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.J Chem Inf Model. 2024 Apr 22;64(8):3488-3502. doi: 10.1021/acs.jcim.4c00023. Epub 2024 Mar 28. J Chem Inf Model. 2024. PMID: 38546820 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources